This multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and tolerability of choline alfoscerate (CA) in treating cognitive impairment in patients with mild to moderate Alzheimer's disease (AD). A total of 261 patients were randomized to receive either CA (400 mg capsules) or placebo, three times daily for 180 days.
